Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
Moodys
Boehringer Ingelheim
McKesson
McKinsey

Last Updated: December 7, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Evobrutinib

See Plans and Pricing

« Back to Dashboard

What is the drug development status for Evobrutinib?

Evobrutinib is an investigational drug.

There have been 6 clinical trials for Evobrutinib. The most recent clinical trial was a Phase 1 trial, which was initiated on August 19th 2019.

The most common disease conditions in clinical trials are Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, and Sclerosis. The leading clinical trial sponsors are EMD Serono Research & Development Institute, Inc., Merck KGaA, and Merck KGaA, Darmstadt, Germany.

There are three US patents protecting this investigational drug and thirty international patents.

Recent Clinical Trials for Evobrutinib
TitleSponsorPhase
Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)Merck KGaA, Darmstadt, GermanyPhase 3
Study of Evobrutinib in Participants With Relapsing Multiple Sclerosis (RMS)EMD Serono Research & Development Institute, Inc.Phase 3
Study of Evobrutinib in Participants With Relapsing Multiple SclerosisMerck KGaA, Darmstadt, GermanyPhase 3

See all Evobrutinib clinical trials

Clinical Trial Summary for Evobrutinib

Top disease conditions for Evobrutinib
Top clinical trial sponsors for Evobrutinib

See all Evobrutinib clinical trials

US Patents for Evobrutinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Evobrutinib   Start Trial Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity Merck Patent GmbH (Darmstadt, DE)   Start Trial
Evobrutinib   Start Trial Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity Merck Patent GmbH (Darmstadt, DE)   Start Trial
Evobrutinib   Start Trial Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity Merck Patent GmbH (Darmstadt, DE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Evobrutinib

Drugname Country Document Number Estimated Expiration Related US Patent
Evobrutinib Australia 2012267491 2031-06-10   Start Trial
Evobrutinib Australia 2017235978 2031-06-10   Start Trial
Evobrutinib Brazil 112013030442 2031-06-10   Start Trial
Evobrutinib Canada 2833771 2031-06-10   Start Trial
Evobrutinib China 103814016 2031-06-10   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
Express Scripts
Baxter
Medtronic
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.